⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18675295 | 1.00 | — | — | |
| SCHEMBL18878187 | 0.86 | L3MBTL1 (0.41) | — | |
| SCHEMBL3033357 | 0.85 | PSEN1 (0.47) | — | |
| SCHEMBL3033354 | 0.85 | PSEN1 (0.47) | — | |
| SCHEMBL15591087 | 0.82 | — | — | |
| SCHEMBL18680863 | 0.82 | — | — | |
| Methyl Alcohol SCHEMBL28457179 | 0.81 | PSEN1 (0.45) | — | |
| SCHEMBL17206982 | 0.79 | DDB1 (0.36) | — | |
| SCHEMBL17032184 | 0.79 | CCR2 (0.33) | — | |
| SCHEMBL18675294 | 0.73 | APOL1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61034013-A | — | — | None | — | — | JP | disclosed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023227695-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
| US-9169240-B2 | Ketone linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-8242285-B2 | N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| CN-101415676-A | N-tert-butoxycarbonyl-2-pyrrolidinone compounds and method for producing the same | SUMITOMO CHEMICAL CO (JP) | 2009-04-22 | — | — | CN | disclosed |
| EP-2008999-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
| JP-S6134013-A | BLOCKING AGENT FOR ISOCYANATE COMPOUND AND ITS USE | SANYO CHEM IND LTD | 1986-02-18 | — | — | JP | disclosed |